keyword
MENU ▼
Read by QxMD icon Read
search

Non Clear Cell RCC

keyword
https://www.readbyqxmd.com/read/28484923/circulating-levels-of-obesity-related-markers-and-risk-of-renal-cell-carcinoma-in-the-plco-cancer-screening-trial
#1
Linda M Liao, Jonathan N Hofmann, Eunyoung Cho, Michael N Pollak, Wong-Ho Chow, Mark P Purdue
PURPOSE: Obesity is an established risk factor for renal cell carcinoma (RCC). It is unclear what biologic mechanisms underlie this association, although recent evidence suggests that the effects of circulating hormones such as insulin-like growth factors (IGF) and adipokines may play a role. METHODS: To address this question, we conducted a nested case-control study of RCC (252 cases, 252 controls) within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial investigating associations with pre-diagnostic serum levels of total adiponectin, high-molecular-weight (HMW) adiponectin, IGF-1, IGF-binding protein-3 (IGFBP-3), and C-peptide...
May 8, 2017: Cancer Causes & Control: CCC
https://www.readbyqxmd.com/read/28466375/impressive-and-durable-response-to-nivolumab-in-a-patient-with-metastatic-type-2-papillary-renal-cell-carcinoma-on-label-but-without-evidence
#2
Diego A Adrianzen Herrera, Sarah B Fleisig, Benjamin A Gartrell
Nivolumab is a treatment option for patients with metastatic renal cell carcinoma (RCC) previously treated with targeted antiangiogenic therapy. Papillary renal cell carcinoma (PRCC) comprises 10-15% of RCC cases but non-clear cell subtypes were excluded from the immunotherapy trials. We report the case of a woman with recurrent metastatic PRCC who had an impressive therapeutic response to nivolumab with no significant adverse events. She had previously been treated with sunitinib and pazopanib with no response...
May 2, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28454375/a-comprehensive-analysis-of-cancer-driving-mutations-and-genes-in-kidney-cancer
#3
Chengmei Long, Jinbo Jian, Xinchang Li, Gongxian Wang, Jingen Wang
An accumulation of driver mutations is important for cancer formation and progression, and leads to the disruption of genes and signaling pathways. The identification of driver mutations and genes has been the subject of numerous previous studies. The present study was performed to identify cancer-driving mutations and genes in renal cell carcinoma (RCC), prioritizing noncoding variants with a high functional impact, in order to analyze the most informative features. Sorting Intolerant From Tolerant (SIFT), Polymorphism Phenotyping version 2 (Polyphen2) and MutationAssessor were applied to predict deleterious mutations in the coding genome...
April 2017: Oncology Letters
https://www.readbyqxmd.com/read/28432616/prognostic-impact-of-pd-1-and-its-ligands-in-renal-cell-carcinoma
#4
REVIEW
Franziska Erlmeier, Wilko Weichert, Andres Jan Schrader, Michael Autenrieth, Arndt Hartmann, Sandra Steffens, Philipp Ivanyi
Programmed death-1 receptor (PD-1) and programmed death-1 receptor-ligand (PD-L1) have been suggested to play a role as prognostic markers in clear cell renal cell carcinoma (ccRCC). The association between PD-L1 and prognosis seems to be more robust than for PD-1. Further, preliminary analyses suggest that neither PD-1 nor its ligands play a role as prognostic markers in non-clear cell RCC, while the prognostic role of PD-L2 in ccRCC as well as in non-clear cell RCC remains unclear.
June 2017: Medical Oncology
https://www.readbyqxmd.com/read/28418903/kinomic-profiling-identifies-focal-adhesion-kinase-1-as-a-therapeutic-target-in-advanced-clear-cell-renal-cell-carcinoma
#5
Arindam P Ghosh, Christopher D Willey, Joshua C Anderson, Karim Welaya, Dongquan Chen, Amitkumar Mehta, Pooja Ghatalia, Ankit Madan, Gurudatta Naik, Sunil Sudarshan, Guru Sonpavde
The introduction of targeted therapies has caused a paradigm shift in the treatment of metastatic clear cell (cc)-renal cell carcinoma (RCC). We hypothesized that determining differential kinase activity between primary and metastatic tumor sites may identify critical drivers of progression and relevant therapeutic targets in metastatic disease. Kinomic profiling was performed on primary tumor and metastatic tumor deposits utilizing a peptide substrate microarray to detect relative tyrosine phosphorylation activity...
April 25, 2017: Oncotarget
https://www.readbyqxmd.com/read/28416105/do-clear-cell-papillary-renal-cell-carcinomas-have-malignant-potential-diolombi-ml-cheng-l-argani-p-epstein-ji-am-j-surg-pathol-december-2015-39-12-1621-1634
#6
Oleksandr N Kryvenko
There have been no recurrences or metastases of clear cell papillary renal cell carcinoma (CCPRCC) in 268 reported cases with follow-up in the English-language literature. We identified all our cases of CCPRCC (1990-2013), reviewing all cases that preceded the formal designation of the entity. Immunohistochemical stains were performed on 32 cases during their initial workup. In addition, stains for carbonic anhydrase IX and cytokeratin 7 were performed on 2 cases, one with atypical follow-up and the other with a more compact morphology, although not performed initially...
April 13, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28411071/predictive-nomogram-for-recurrence-following-surgery-for-non-metastatic-renal-cell-cancer-with-tumor-thrombus
#7
E Jason Abel, Timothy A Masterson, Jose A Karam, Viraj A Master, Vitaly Margulis, Ryan Hutchinson, C Adam Lorentz, Evan Bloom, Tyler M Bauman, Christopher G Wood, Michael L Blute
BACKGROUND: Following surgery for non-metastatic renal cell carcinoma (RCC) with tumor thrombus, the risk of recurrence is significant but variable among individual patients. The purpose of this study is to develop and validate a predictive nomogram for individual estimation of recurrence risk following surgery for RCC with venous tumor thrombus. METHODS: Comprehensive data was collected for non-metastatic RCC patients with thrombus treated at 5 institutions from 2000-2013...
April 11, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28410911/comprehensive-analysis-of-survival-outcomes-in-non-clear-cell-renal-cell-carcinoma-patients-treated-in-clinical-trials
#8
Guillermo de Velasco, Rana R McKay, Xun Lin, Raphel B Moreira, Ronit Simantov, Toni K Choueiri
BACKGROUND: Clinical data from patients with non-clear cell renal cell carcinoma (nccRCC) receiving targeted therapy are limited, and many clinical trials have excluded these patients from study entry. We sought to investigate the outcomes of patients with nccRCC treated in clinical trials in the modern era compared with the outcomes of patients with clear cell RCC (ccRCC). PATIENTS AND METHODS: We conducted a retrospective study of patients with metastatic RCC who had received targeted therapy in Pfizer-sponsored phase II and III clinical trials from 2003 to 2013...
March 21, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28408296/percutaneous-radiofrequency-ablation-for-renal-cell-carcinoma-vs-partial-nephrectomy-comparison-of-long-term-oncologic-outcomes-in-both-clear-cell-and-non-clear-cell-of-the-most-common-subtype
#9
Ning Liu, Daoguang Huang, Xiangming Cheng, Yankun Chong, Wei Wang, Weidong Gan, Hongqian Guo
OBJECTIVES: To compare the clinical outcomes of percutaneous radiofrequency ablation (PRFA) and partial nephrectomy (PN) in patients with clear cell renal cell carcinoma (ccRCC) and non-clear cell RCC (nccRCC) of the most common subtypes. MATERIALS AND METHODS: A retrospective study was conducted to review the records of all the patients who underwent PRFA or PN between February 2005 and April 2014 at our institution. Patients with histologic confirmation of ccRCC, papillary RCC, and chromophobe RCC were included...
April 10, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28404888/ecto-5-nucleotidase-cd73-is-a-biomarker-for-clear-cell-renal-carcinoma-stem-like-cells
#10
Lei Song, Wenling Ye, Yong Cui, Jianzhong Lu, Yanan Zhang, Nan Ding, Wentao Hu, Hailong Pei, Zhongjin Yue, Guangming Zhou
Identification of a specific biomarker for cancer stem cells (CSCs) is of potential applications in the development of effective therapeutic strategies for renal cell carcinoma (RCC). In this study, both the RCC cell line 786-O and surgically removed clear cell RCC (ccRCC) tissues were implemented to grew as spheroids in serum-free medium supplemented with mitogens. This subpopulation possessed key characteristics defining CSCs. We also identified that surgically removed ccRCC tissues were heterogenic and there was a subpopulation of cells that was highly stained with rhodamine-123...
May 9, 2017: Oncotarget
https://www.readbyqxmd.com/read/28349447/overexpression-of-placenta-specific-8-is-associated-with-malignant-progression-and-poor-prognosis-of-clear-cell-renal-cell-carcinoma
#11
Liping Shi, Long Xiao, Baoli Heng, Shijie Mo, Weijun Chen, Zexuan Su
BACKGROUND: Placenta specific 8 (PLAC8) plays an important role in many different cellular processes and human diseases, including multiple types of cancer. However, the functional role of PLAC8 in clear cell renal cell carcinoma (ccRCC) has never been elucidated. METHODS: PLAC8 mRNA expression was investigated in 31 pairs of fresh ccRCC tumor tissues and matched adjacent non-tumor tissues by RT-qPCR and confirmed by analyzing the TCGA KRCC dataset which contains RNA-seq data of 534 ccRCC and 72 solid normal tissues...
March 27, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28336290/serum-microrna-expression-profiling-potential-diagnostic-implications-of-a-panel-of-serum-micrornas-for-clear-cell-rcc
#12
Siddharth Yadav, Madhuram Khandelwal, Amlesh Seth, Ashish K Saini, Prem N Dogra, Alpana Sharma
OBJECTIVE: To study the expression profiles of 5 microRNAs in tissue and serum of patients with clear cell RCC (ccRCC) and evaluate their diagnostic and prognostic potential. MATERIAL & METHODS: We prospectively analyzed 30 patients of histologically proven ccRCC and collected 3 ml of serum pre-operatively and small pieces of tumor and adjacent non-tumor renal tissue intra-operatively. Control serum samples were obtained from 15 patients of non renal benign diseases...
March 20, 2017: Urology
https://www.readbyqxmd.com/read/28300276/reassessing-the-clinical-spectrum-associated-with-hereditary-leiomyomatosis-and-renal-cell-carcinoma-syndrome-in-french-fh-mutation-carriers
#13
M Muller, S Ferlicot, M Guillaud-Bataille, G Le Teuff, C Genestie, S Deveaux, A Slama, N Poulalhon, B Escudier, L Albiges, N Soufir, M-F Avril, B Gardie, C Saldana, Y Allory, A-P Gimenez-Roqueplo, B Bressac-de Paillerets, S Richard, P R Benusiglio
We addressed uncertainties regarding hereditary leiomyomatosis and renal cell carcinoma (HLRCC) by exploring all French cases, representing the largest series to date. Fumarate hydratase (FH) germline testing was performed with Sanger sequencing and qPCR/MLPA. Enzyme activity was measured when necessary. We carried out whenever possible a pathology review of RCC and S-(2-succino)-cysteine (2SC)/fumarate hydratase immunohistochemistry. We estimated survival using non-parametric Kaplan-Meier. There were 182 cases from 114 families...
March 16, 2017: Clinical Genetics
https://www.readbyqxmd.com/read/28258962/renal-cell-carcinoma-with-pulmonary-metastasis-and-metachronous-non-small-cell-lung-cancer
#14
Isaac A Bowman, Ivan Pedrosa, Payal Kapur, James Brugarolas
INTRODUCTION: The development of a second primary malignancy in a patient with a preexisting diagnosis of metastatic cancer may be easily overlooked or misattributed to progression of disease. We report 3 patients with clear-cell renal cell carcinoma (RCC) metastatic to the lungs who were subsequently diagnosed with non-small-cell lung cancer (NSCLC). We examined the frequency of this occurrence within our institution and report on the radiographic findings that may help distinguish between metastatic RCC and primary lung cancers...
February 6, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28251886/highly-expressed-antisense-non-coding-rna-in-the-ink4-locus-promotes-5-growth-and-invasion-of-renal-clear-carcinoma-cells-via-the-%C3%AE-catenin-pathway
#15
Qingchun Li, Yuan Tian, Guangrui Hu, Yun Liang, Wei Bai, Hongjun Li
Long non-coding RNAs (LncRNAs) antisense non-coding RNA in the INK4 locus (ANRIL) is involved in several human cancers.However, the role of ANRIL in renal cell carcinoma (RCC) remains unclear. This study was aimed to explore whether and how ANRIL affects the RCC progression. First of all, the expression of ANRIL in clinical tumor tissues and 4 kinds of RCC cell lines were evaluated. After transfection, the cell viability, colony number, apoptosis, migration and invasion were all assessed. Then, the expression of proteins related to apoptosis, epithelial to mesenchymal transition (EMT) and β-catenin signaling pathway were all assessed...
March 2, 2017: Oncology Research
https://www.readbyqxmd.com/read/28188091/a-prospective-multicenter-analysis-of-pseudocapsule-characteristics-do-all-stages-of-renal-cell-carcinoma-have-complete-pseudocapsules
#16
Seok Cho, Jeong Hyeon Lee, Seung Hyun Jeon, Jinsung Park, Sang Hyub Lee, Chul Hwan Kim, Ji-Youn Sung, Joo Heon Kim, Jong Hyun Pyun, Jeong Gu Lee, Je Jong Kim, Jun Cheon, Sung Gu Kang, Seok Ho Kang
OBJECTIVES: To assess the characteristics of pseudocapsule (PC) in localized renal cell carcinoma (RCC) by analyzing the rates of completeness of PC and pseudocapsular invasion and clinical and pathological risk factors of it. MATERIALS AND METHODS: Between February 2013 and September 2015, data were gathered prospectively from 180 consecutive patients who underwent partial nephrectomy or radical nephrectomy at 3 institutions, and 161 were enrolled. Evaluated factors included age and sex; histologic factors such as tumor diameter, stage, tumor subtype, necrosis, and Fuhrman grade; and clinical factors such as RENAL score; and completeness of PC...
February 7, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28144152/overall-survival-in-renal-cell-carcinoma-after-introduction-of-targeted-therapies-a-norwegian-population-based-study
#17
Christian Beisland, Tom B Johannesen, Olbjorn Klepp, Ulrika Axcrona, Knut Martin Torgersen, Jan Kowalski, Oddvar Solli, Rickard Sandin, Jan Oldenburg
BACKGROUND: This population-wide retrospective, non-interventional registry study assessed changes in overall survival (OS) and factors influencing OS in Norwegian patients with renal cell carcinoma (RCC). METHODS: Two population-wide health registries were used to identify all RCC patients with (mRCC) or without metastases diagnosed before (2002-2005) and after (2006-2008 and 2009-2011) introduction of targeted therapies. Median OS was estimated using Kaplan-Meier method...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28070921/brm-smarca2-negative-clear-cell-renal-cell-carcinoma-is-associated-with-a-high-percentage-of-brm-somatic-mutations-deletions-and-promoter-methylation
#18
Qiu-Yuan Xia, Xue-Mei Zhan, Xiang-Shan Fan, Sheng-Bing Ye, Shan-Shan Shi, Rui Li, Xue Wei, Xuan Wang, Heng-Hui Ma, Zhen-Feng Lu, Xiao-Jun Zhou, Qiu Rao
AIMS: The aim of this study was to investigate potential molecular mechanisms associated with loss of BRM expression in poorly differentiated clear cell renal cell carcinoma (ccRCC). METHODS AND RESULTS: Nineteen previously selected BRM-negative RCC tissues were examined by DNA sequencing, fluorescence in-situ hybridization (FISH) and methylation-specific polymerase chain reaction (PCR) of the BRM gene. BRM mutation was identified in 78.9% (15 of 19) cases, chromosome 9 monosomy or BRM deletion in 43...
April 2017: Histopathology
https://www.readbyqxmd.com/read/28025654/subjective-and-objective-heterogeneity-scores-for-differentiating-small-renal-masses-using-contrast-enhanced-ct
#19
Shuai Leng, Naoki Takahashi, Daniel Gomez Cardona, Kazuhiro Kitajima, Brian McCollough, Zhoubo Li, Akira Kawashima, Bradley C Leibovich, Cynthia H McCollough
PURPOSE: The aim of this study was to assess the effect of denoising on objective heterogeneity scores and its diagnostic capability for the diagnosis of angiomyolipoma (AML) and renal cell carcinoma (RCC). MATERIALS AND METHODS: A total of 158 resected renal masses ≤4 cm [98 clear cell (cc) RCCs, 36 papillary (pap)-RCCs, and 24 AMLs] from 139 patients were evaluated. A representative contrast-enhanced computed tomography (CT) image for each mass was selected by a genitourinary radiologist...
May 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/27969569/biology-and-treatment-of-renal-tumours-in-childhood
#20
REVIEW
Jesper Brok, Taryn D Treger, Saskia L Gooskens, Marry M van den Heuvel-Eibrink, Kathy Pritchard-Jones
In Europe, almost 1000 children are diagnosed with a malignant renal tumour each year. The vast majority of cases are nephroblastoma, also known as Wilms' tumour (WT). Most children are treated according to Société Internationale d'Oncologie Pédiatrique Renal Tumour Study Group (SIOP-RTSG) protocols with pre-operative chemotherapy, surgery, and post-operative treatment dependent on stage and histology. Overall survival approaches 90%, but a subgroup of WT, with high-risk histology and/or relapsed disease, still have a much poorer prognosis...
October 28, 2016: European Journal of Cancer
keyword
keyword
104989
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"